These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3118800)

  • 21. Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
    Arca-Suárez J; Fraile-Ribot P; Vázquez-Ucha JC; Cabot G; Martínez-Guitián M; Lence E; González-Bello C; Beceiro A; Rodríguez-Iglesias M; Galán-Sánchez F; Bou G; Oliver A
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal Evolution of the Pseudomonas-Derived Cephalosporinase (PDC) Structure and Activity in a Cystic Fibrosis Patient Treated with β-Lactams.
    Colque CA; Albarracín Orio AG; Tomatis PE; Dotta G; Moreno DM; Hedemann LG; Hickman RA; Sommer LM; Feliziani S; Moyano AJ; Bonomo RA; K Johansen H; Molin S; Vila AJ; Smania AM
    mBio; 2022 Oct; 13(5):e0166322. PubMed ID: 36073814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations.
    Wu YL; Scott EM; Po AL; Tariq VN
    APMIS; 1999 Jun; 107(6):585-92. PubMed ID: 10379686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study.
    Llanes C; Pourcel C; Richardot C; Plésiat P; Fichant G; Cavallo JD; Mérens A;
    J Antimicrob Chemother; 2013 Aug; 68(8):1763-71. PubMed ID: 23629014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective survey of beta-lactamases produced by ceftazidime- resistant Pseudomonas aeruginosa isolated in a French hospital in 2000.
    De Champs C; Poirel L; Bonnet R; Sirot D; Chanal C; Sirot J; Nordmann P
    Antimicrob Agents Chemother; 2002 Sep; 46(9):3031-4. PubMed ID: 12183264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
    Pedersen SS; Pressler T; Jensen T; Rosdahl VT; Bentzon MW; Høiby N; Koch C
    J Antimicrob Chemother; 1987 Jan; 19(1):101-7. PubMed ID: 3104273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
    Bilal H; Tait JR; Lang Y; Zhou J; Bergen PJ; Peleg AY; Bulitta JB; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0220321. PubMed ID: 35041509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Marley EF; Mohla C; Campos JM
    J Clin Microbiol; 1995 Dec; 33(12):3191-3. PubMed ID: 8586700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison between the in-vitro activity of new agents on Pseudomonas aeruginosa isolates from cystic fibrosis patients and other chronic infections.
    Gordts B; Vandenborre C; VanderAuwera P; Butzler JP
    J Antimicrob Chemother; 1984 Jul; 14(1):25-9. PubMed ID: 6434504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Widespread detection of VEB-1-type extended-spectrum beta-lactamases among nosocomial ceftazidime-resistant Pseudomonas aeruginosa isolates in Sofia, Bulgaria.
    Strateva T; Ouzounova-Raykova V; Markova B; Todorova A; Marteva-Proevska Y; Mitov I
    J Chemother; 2007 Apr; 19(2):140-5. PubMed ID: 17434821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM; Choi JY; Lee JY; Kang CI; Chung DR; Peck KR; Song JH; Ko KS
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outbreak of PER-1 and diversity of β-lactamases among ceftazidime-resistant Pseudomonas aeruginosa clinical isolates.
    Qing Y; Cao KY; Fang ZL; Huang YM; Zhang XF; Tian GB; Huang X
    J Med Microbiol; 2014 Mar; 63(Pt 3):386-392. PubMed ID: 24398232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the
    Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
    Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
    [No Abstract]   [Full Text] [Related]  

  • 36. Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients.
    Bingen E; Denamur E; Picard B; Goullet P; Lambert-Zechovsky N; Foucaud P; Navarro J; Elion J
    Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):432-7. PubMed ID: 1358612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.
    Kuti JL; Pettit RS; Neu N; Cies JJ; Lapin C; Muhlebach MS; Novak KJ; Nguyen ST; Saiman L; Nicolau DP
    Diagn Microbiol Infect Dis; 2015 Sep; 83(1):53-5. PubMed ID: 26003469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1990 Mar; 34(3):487-8. PubMed ID: 2110438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Vickery SB; McClain D; Wargo KA
    Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients.
    Zamorano L; Juan C; Fernández-Olmos A; Ge Y; Cantón R; Oliver A
    Clin Microbiol Infect; 2010 Sep; 16(9):1482-7. PubMed ID: 20002107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.